<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266031</url>
  </required_header>
  <id_info>
    <org_study_id>999916116</org_study_id>
    <secondary_id>16-C-N116</secondary_id>
    <nct_id>NCT01266031</nct_id>
  </id_info>
  <brief_title>Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma</brief_title>
  <official_title>Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brain Tumor Trials Collaborative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University Wexner Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University Feinberg School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UF Health Cancer Center at Orlando Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MUSC Hollings Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Oncology-Austin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this Phase I portion of this clinical research study is to find the highest
      tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with
      malignant gliomas. The safety of these drug combinations will also be studied.

      The goal of this Phase II part of this clinical research study is to learn if bevacizumab
      when given with or without vorinostat can help to control malignant gliomas. The safety of
      these drug combinations will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

        -  Glioblastoma (GBM) is the most common primary brain tumor. With optimal treatment,
           consisting of focal radiotherapy with concurrent chemotherapy, followed by adjuvant
           chemotherapy, median survival is 14.6 months. Most patients have evidence of tumor
           progression within one year of diagnosis despite treatment. At progression, treatment
           options are limited and mostly ineffective.

        -  Given the importance of angiogenesis in GBM, anti-angiogenic therapy is a promising
           strategy in recurrent GBM. Bevacizumab, the first angiogenesis inhibitor approved
           against cancer by FDA based on improved survival of advanced colon cancer patient, has
           recently been studied in the GBM.

        -  The present study aims to determine the potential of vorinostat, an HDAC inhibitor plus
           bevacizumab, versus bevacizumab alone, in an attempt to increase the anti-angiogenic
           effects of VEGF by blocking the evasive resistance by combination with vorinostat and to
           also not only provide the potential of the independent effects of both agents but also
           the potential for synergy.

      Objectives

        -  To determine the maximum tolerated dose (MTD) of vorinostat plus bevacizumab in adult
           patients with malignant glioma.

        -  To determine the efficacy of vorinostat plus bevacizumab versus bevacizumab alone in
           patients with recurrent WHO grade IV glioma (glioblastoma and gliosarcoma) as determined
           by progression free survival (PFS) using an adaptive randomization phase II trial
           design.

      Eligibility

        -  Patients must have histologically proven glioblastoma, gliosarcoma or anaplastic glioma
           to be eligible for the Phase I component of this protocol. Anaplastic gliomas include
           anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed
           oligoastrocytoma (AMO), or malignant glioma NOS (not otherwise specified). Patients will
           be eligible if the original histology was low-grade glioma and a subsequent histological
           diagnosis of a malignant glioma is made. Only patients with histologically proven or
           imaging proven recurrent glioblastoma or gliosarcoma will be eligible for the Phase II
           component.

        -  Patients must have shown unequivocal evidence for tumor progression as determined by an
           MRI scan done prior to study entry which will be reviewed by the treating physician to
           confirm and document recurrence.

        -  No prior treatment with bevacizumab or Vorinostat

      Design

      The phase I component will assess the MTD of Vorinostat in combination with Bevacizumab. A
      conventional phase I design will be used and the MTD will be selected using a 3+3 accrual
      design at each dose level until MTD is determined. A maximum of 18 patients will be recruited
      to this component of the study.

      The phase II component of the trial compares Bevacizumab to Vorinostat+ Bevacizumab in
      patients with recurrent GBM. The primary outcome is progression free survival. Patients will
      be randomized between the two arms using a Bayesian adaptive algorithm. Patients will be
      randomized fairly between the two arms at the start of the trial (for the first 20 patients).
      Thereafter, as the trial progresses and data accrue, the randomization will become unbalanced
      in favor of the treatment that, on average, has better results in terms of failure time.
      Therefore, each successive patient is more likely to receive the treatment with better
      results, on average. A minimum of 20 and a maximum of 90 patients will be accrued.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2011</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) at 6 Months</measure>
    <time_frame>Baseline until disease progression or death due to any cause, up to six months</time_frame>
    <description>PFS is time measured in months to disease progression as assessed at six months from participant registration. Assessments continue every 8 weeks up to 28 days after last dose (follow-up), anticipated trial length one year.
Participants must be assessed at least 4 weeks after surgery to begin treatment in the adaptive randomized Phase 2 portion of the trial. PFS in participants in the surgical arm determined from the date of randomization to the treatment arms and not from the date of registration in the trial.
Study outcome measure period ended June 2015.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Oral Vorinostat Used With Bevacizumab</measure>
    <time_frame>28 day, cycle 1</time_frame>
    <description>MTD defined as the dose level at which 1/6 patients experience dose limiting toxicity (DLT), using conventional Phase I design where the MTD was selected using a 3+3 accrual design at each dose level until MTD was determined. Toxicities will be graded according to the Common Terminology Criteria for Adverse events (CTCAE) Version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Time between the first day of treatment to the day of disease progression.</time_frame>
    <description>Time between the first day of treatment to the day of disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time between the first day of treatment to the day of death.</time_frame>
    <description>Time between the first day of treatment to the day of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Bevacizumab With and Without Vorinostat Upon Biomarkers of Angiogenesis</measure>
    <time_frame>Baseline before treatment, Cycle 1 Day 2, day 15 (pre-infusion and post-infusion), Cycle 2 (pre-infusion)</time_frame>
    <description>About 5cc of blood was collected to measure plasma angiogenic proteins vascular endothelial growth factor (VEGF), placental growth factor (PIGF), basic fibroblast growth factor (bFGF), stromal cell-derived factor α (SDF1α), angiopoietin 1 and 2 by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Severity of the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT)</measure>
    <time_frame>Baseline, week 4, week 8, and end of therapy</time_frame>
    <description>Proportion of patients rating their symptoms to be 7 or greater on a 0-10 scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool. Zero is &quot;not present&quot; and 10 is &quot;as bad as you can imagine. All patients with at least one valid questionnaire will be included in the anlyses. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity and symptom interference measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Core Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool</measure>
    <time_frame>Baseline, week 4, week 8, and end of therapy</time_frame>
    <description>Proportion of patients rating their symptoms to be 7 or greater on a 0-10 scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool. Zero is &quot;not present&quot; and 10 is &quot;as bad as you can imagine. All patients with at least one valid questionnaire will be included in the anlyses. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity and symptom interference measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Symptom Interference at the Time of Clinical Evaluation</measure>
    <time_frame>Baseline, week 4, week 8, and end of therapy</time_frame>
    <description>Proportion of patients rating their symptoms to be 7 or greater on a 0-10 scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool. Zero is &quot;not present&quot; and 10 is &quot;as bad as you can imagine. All patients with at least one valid questionnaire will be included in the anlyses. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity and symptom interference measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Response</measure>
    <time_frame>End of therapy</time_frame>
    <description>Magnetic resonance imaging (MRI) and contrast-enhanced (CE) MRI was used to evaluate tumor response. Response is defined by the Modified MacDonald criteria. Complete Response (CR) is complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. Partial Response, Non-Measurable (PRNM) is not applicable. Stable/No Response does not qualify for CR, PR or progression. Progression is 25% increase in the sum of products, of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any lesion/site, OR failure to return for evaluation due to health or deteriorating condition (unless clearly unrelated to this cancer).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Malignant Glioma</condition>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vorinostat and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vorinostat: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.
Bevacizumab: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.</description>
    <arm_group_label>Vorinostat and Bevacizumab</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_label>Vorinostat and Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients will be included in the study based on the following criteria.

          -  Patients must have histologically proven glioblastoma, gliosarcoma or anaplastic
             glioma to be eligible for the Phase I component of this protocol. Anaplastic gliomas
             include anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic
             mixed oligoastrocytoma (AMO), or malignant glioma NOS (not otherwise specified).
             Patients will be eligible if the original histology was low-grade glioma and a
             subsequent histological diagnosis of a malignant glioma is made. Only patients with
             histologically proven or imaging proven recurrent glioblastoma or gliosarcoma will be
             eligible for the Phase II component. Wafer acceptable if recurrence is confirmed.

          -  All patients must sign an informed consent indicating their awareness of the
             investigational nature of this study. Patients must have signed an authorization for
             the release of their protected health information.

          -  Patients must be 18 years old or older.

          -  Patients must have a Karnofsky performance status (KPS) equal or greater than 60

          -  At the time of registration:

               -  Patients must have recovered from the toxic effects of prior therapy to &lt; grade 2
                  toxicity per CTC version 4 (except deep vein thrombosis )

                    1. 28 days from any investigational agent,

                    2. 4 weeks (28 days) from prior cytotoxic therapy,

                    3. 2 weeks (14 days) from vincristine,

                    4. 6 weeks (42 days) from nitrosoureas,

                    5. 3 weeks (21 days) from procarbazine administration,

                    6. greater than or equal to1 week (7 days) for non-cytotoxic agents, e.g.,
                       interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer
                       does not count).

          -  Patients who receive anticancer agents for non-therapeutic purposes unrelated to this
             study (such as presurgically for obtaining pharmacology data for the agent) will be
             eligible to enter the study provided they have recovered from the toxic effects of the
             agent if any. Any questions related to the definition of noncytotoxic agents should be
             directed to the Study Chair.

          -  Patients must have adequate bone marrow function (ANC greater than or equal to
             1,500/mm3, platelet count of greater than or equal to 100,000/mm3), adequate liver
             function (SGPT less than or equal to 3 times upper limit normal and alkaline
             phosphatase less than or equal to 2 times upper limit normal, total bilirubin less
             than or equal to 1.5mg/dl, Patients with high bilirubin levels related to known
             diagnosis of benign hyperbilirubinemia (Gilbert s syndrome) will be eligible ., and
             adequate renal function (BUN less than or equal to 1.5 times institutional normal and
             Creatinine &lt; 1.5 mg/dl) prior to registration. These tests must be performed within 14
             days prior to registration.

          -  Patients must have shown unequivocal evidence for tumor progression as determined by
             an MRI scan done prior to study entry which will be reviewed by the treating physician
             to confirm and document recurrence.

        Patients with prior therapy that included interstitial brachytherapy or stereotactic
        radiosurgery must have confirmation of true progressive disease rather than radiation
        necrosis using the local institutional standards for such determination including advanced
        imaging or surgery.

          -  The baseline on-study MRI scan should be performed within 14 days (+ 3 working days)
             prior to registration but before starting treatment and on a steroid dose that has
             been stable or decreasing for at least 5 days. If the steroid dose is increased
             between the date of imaging and registration (or at that time), a new baseline MRI is
             required. The same type of scan, i.e., MRI must be used throughout the period of
             protocol treatment for tumor measurement.

          -  Patients having undergone recent resection of recurrent or progressive tumor will be
             eligible as long as all of the following conditions apply:

               1. At least 4 weeks (28 days ) have elapsed from the date of surgery and the
                  patients have recovered from the effects of surgery.

               2. Evaluable or measureable disease following resection of recurrent Malignant
                  Glioma is not mandated for eligibility into the study.

               3. To best assess the extent of residual disease post-operatively, a MRI should be
                  done no later than 96 hours in the immediate post-operative period or at least 4
                  weeks post-operatively, within 14 days prior to registration. If the 96-hour scan
                  is more than 14 days before registration, the scan needs to be repeated. If the
                  steroid dose is increased between the date of imaging and registration, a new
                  baseline MRI is required on a stable steroid dosage for at least 5 days.

          -  Patients must have failed prior radiation therapy and must have an interval of greater
             than or equal to 12 weeks (84 days) from the completion of radiation therapy to study
             entry except if there is unequivocal evidence for tumor recurrence (such as
             histological confirmation or advanced imaging data such as PET scan) in which case at
             least 4 weeks (28 days) from completion of radiation therapy will suffice.

          -  Patients with prior therapy that included interstitial brachytherapy or stereotactic
             radiosurgery must have confirmation of true progressive disease rather than radiation
             necrosis based upon either PET or Thallium scanning, MR spectroscopy or
             surgical/pathological documentation of disease.

          -  Women of childbearing potential must have a negative B-HCG pregnancy test documented
             within 14 days prior to registration. Women of childbearing potential must not be
             pregnant, must not be breast-feeding, and must practice adequate contraception for the
             duration of the study, and for 30 days after the last dose of study medication.
             Patients must not be pregnant because animal studies show that bevacizumab and
             Vorinostat are teratogenic.

          -  Male patients on treatment with Vorinostat must agree to use an adequate method of
             contraception for the duration of the study, and for 30 days after the last dose of
             study medication.

          -  Patient must be able to tolerate the procedures required in this study including
             periodic blood sampling, study related assessments, and management at the treating
             institution for the duration of the study.

          -  Patients receiving treatment with any antiepileptic medications except Valproic acid
             (because of its HDAC inhibitory activity) can be included in the study. Vorinostat is
             not metabolized by Cytochrome P450 3A4 (CYP 3A4); however, Vorinostat may potentially
             suppress CYP 3A4 activity. Therefore, patients should preferably be treated with
             nonenzyme inducing anti-epileptic medications although this is not mandatory. If
             enzymeinducing antiepileptic drugs are used, monitoring of these drug levels should be
             considered, as considered clinically appropriate by the treating physician.

          -  For the Phase II portion of the study, patients may have had treatment for no more
             than 2 prior relapses. There is no limit to the number of relapses for the phase I
             portion of the study provided the functional status and other eligibility criteria for
             enrollment are met. Relapse is defined as progression following initial therapy (i.e.
             radiation+/- chemo if that was used as initial therapy). The intent therefore is that
             patients had no more than 3 prior therapies (initial and treatment for 2 relapses). If
             the patient had a surgical resection for relapsed disease and no anti-cancer therapy
             was instituted for up to 12 weeks, and the patient undergoes another surgical
             resection, this is considered as 1 relapse. For patients who had prior therapy for a
             low-grade glioma, the surgical diagnosis of a high-grade glioma will be considered the
             first relapse

        EXCLUSION CRITERIA:

        General Exclusion Criteria

          -  Inability to comply with protocol or study procedures (for example, an inability to
             swallow tablets).

          -  Prior treatment with bevacizumab or Vorinostat.

          -  Patients receiving valproic acid (VPA), an anticonvulsant drug with HDAC inhibitor
             properties, will be excluded, unless they are switched to an alternative agent prior
             to treatment initiation. A 5-day wash out period is required. Patients who have failed
             prior treatment with other histone deacetylase inhibitors will be excluded.

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from providing informed consent.

          -  Any condition, including the presence of clinically significant laboratory
             abnormalities, which places the patient at unacceptable risk if he/she were to
             participate in the study or confounds the ability to interpret data from the study.
             These would include

               1. Active infection (including persistent fever) including known AIDS or Hepatitis C
                  infection

               2. Diseases or conditions that obscure toxicity or dangerously alter drug metabolism

               3. Serious intercurrent medical illness (e.g. symptomatic congestive heart failure).

          -  Current, recent (within 4 weeks (28 days) of the first infusion of this study, or
             planned participation in an experimental antitumor drug study (other than the current
             one).

          -  Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix or bladder), unless in complete remission and off of
             all therapy for that disease for a minimum of 3 years are ineligible.

          -  Patients with spinal disease (metastasis) and/or leptomeningeal disease will not be
             allowed in the study.

        Bevacizumab-Specific Exclusion Criteria

          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt; 140 mmHg
             and/or diastolic blood pressure &gt; 90 mmHg).

          -  Prior history of hypertensive encephalopathy.

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure.

          -  History of myocardial infarction or unstable angina within 6 months prior to Day 1.

          -  History of stroke or transient ischemic attack within 6 months prior to Day1.

          -  Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or
             recent peripheral arterial thrombosis) within 6 months prior to Day 1.

          -  History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per
             episode) within 1 month prior to Day 1.

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation).

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1 or anticipation of need for major surgical procedure during the course
             of the study. Patients with recent resection will be eligible for entry into the
             surgical arm of the study but will follow guidelines as in section 4.9 .

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to Day 1.

          -  History of abdominal fistula or gastrointestinal perforation within 6 months prior to
             Day 1.

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture.

          -  Proteinuria as demonstrated by:

               -  Urine protein: creatinine (UPC) ratio greater than or equal to 1.0 at screening
                  OR

               -  Urine dipstick for proteinuria greater than or equal to 2+ (patients discovered
                  to have greater than or equal to 2+ proteinuria on dipstick urinalysis at
                  baseline should undergo a 24 hour urine collection and must demonstrate less than
                  or equal to 1g of protein in 24 hours to be eligible).

          -  Known hypersensitivity to any component of bevacizumab.

          -  Pregnancy (positive pregnancy test) or lactation. Use of effective means of
             contraception (men and women) in subjects of child-bearing potential is required for
             study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R Gilbert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <results_first_submitted>March 15, 2016</results_first_submitted>
  <results_first_submitted_qc>August 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2016</results_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Mark Gilbert, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: the study was initially written in 2010 and eventually activated at the lead site on 7/6/2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vorinostat + Bevacizumab</title>
          <description>Phase I Vorinostat starting dose 400 mg orally days 1 - 7 &amp; days 15 - 21 in combination with Bevacizumab fixed dose 10mg/kg IV on Days 1 &amp; 15 of 28 day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Bevacizumab</title>
          <description>Phase II Bevacizumab 10 mg/kg/dose IV on days 1 &amp; 15 of a 28 day cycle.</description>
        </group>
        <group group_id="P3">
          <title>Bevacizumab + Vorinostat 400 mg</title>
          <description>Phase II Bevacizumab 10 mg/kg/dose IV Day 1 &amp; 15 + MTD of Vorinostat 400 mg/day by mouth on days 1 to 7 &amp; days 15 to 21 of a 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vorinostat + Bevacizumab</title>
          <description>Phase I Vorinostat starting dose 400 mg orally days 1 - 7 and days 15 - 21 in combination with Bevacizumab fixed dose 10mg/kg IV on Days 1 + 15 of 28 day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Bevacizumab</title>
          <description>Phase II Bevacizumab 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Bevacizumab + Vorinostat 400 mg</title>
          <description>Phase II Bevacizumab 10 mg/kg/dose IV Day 1 &amp; 15 + MTD of Vorinostat 400 mg/day by mouth on days 1 to 7 &amp; days 15 to 21 of a 28 day cycle.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" lower_limit="18" upper_limit="66"/>
                    <measurement group_id="B2" value="60" lower_limit="27" upper_limit="88"/>
                    <measurement group_id="B3" value="57" lower_limit="22" upper_limit="75"/>
                    <measurement group_id="B4" value="57" lower_limit="18" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) at 6 Months</title>
        <description>PFS is time measured in months to disease progression as assessed at six months from participant registration. Assessments continue every 8 weeks up to 28 days after last dose (follow-up), anticipated trial length one year.
Participants must be assessed at least 4 weeks after surgery to begin treatment in the adaptive randomized Phase 2 portion of the trial. PFS in participants in the surgical arm determined from the date of randomization to the treatment arms and not from the date of registration in the trial.
Study outcome measure period ended June 2015.</description>
        <time_frame>Baseline until disease progression or death due to any cause, up to six months</time_frame>
        <population>Of the 90 participants (Bev+V: 49, Bev: 41) enrolled, 83 were evaluable for the primary endpoint (Bev+V: 46, Bev: 37).</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab</title>
            <description>Phase II Bevacizumab 10 mg/kg/dose IV on days 1 &amp; 15 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + Vorinostat 400 mg</title>
            <description>Phase II Bevacizumab 10 mg/kg/dose IV Day 1 &amp; 15 + MTD of Vorinostat 400 mg/day by mouth on days 1 to 7 &amp; days 15 to 21 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) at 6 Months</title>
          <description>PFS is time measured in months to disease progression as assessed at six months from participant registration. Assessments continue every 8 weeks up to 28 days after last dose (follow-up), anticipated trial length one year.
Participants must be assessed at least 4 weeks after surgery to begin treatment in the adaptive randomized Phase 2 portion of the trial. PFS in participants in the surgical arm determined from the date of randomization to the treatment arms and not from the date of registration in the trial.
Study outcome measure period ended June 2015.</description>
          <population>Of the 90 participants (Bev+V: 49, Bev: 41) enrolled, 83 were evaluable for the primary endpoint (Bev+V: 46, Bev: 37).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="1.8" upper_limit="5.8"/>
                    <measurement group_id="O2" value="3.6" lower_limit="2.2" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Oral Vorinostat Used With Bevacizumab</title>
        <description>MTD defined as the dose level at which 1/6 patients experience dose limiting toxicity (DLT), using conventional Phase I design where the MTD was selected using a 3+3 accrual design at each dose level until MTD was determined. Toxicities will be graded according to the Common Terminology Criteria for Adverse events (CTCAE) Version 4.0.</description>
        <time_frame>28 day, cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat + Bevacizumab</title>
            <description>Phase I Vorinostat starting dose 400 mg orally days 1 - 7 &amp; days 15 - 21 in combination with Bevacizumab fixed dose 10mg/kg IV on Days 1 &amp; 15 of 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Oral Vorinostat Used With Bevacizumab</title>
          <description>MTD defined as the dose level at which 1/6 patients experience dose limiting toxicity (DLT), using conventional Phase I design where the MTD was selected using a 3+3 accrual design at each dose level until MTD was determined. Toxicities will be graded according to the Common Terminology Criteria for Adverse events (CTCAE) Version 4.0.</description>
          <units>mg/day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>Time between the first day of treatment to the day of disease progression.</description>
        <time_frame>Time between the first day of treatment to the day of disease progression.</time_frame>
        <posting_date>01/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Time between the first day of treatment to the day of death.</description>
        <time_frame>Time between the first day of treatment to the day of death.</time_frame>
        <posting_date>01/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Bevacizumab With and Without Vorinostat Upon Biomarkers of Angiogenesis</title>
        <description>About 5cc of blood was collected to measure plasma angiogenic proteins vascular endothelial growth factor (VEGF), placental growth factor (PIGF), basic fibroblast growth factor (bFGF), stromal cell-derived factor α (SDF1α), angiopoietin 1 and 2 by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Baseline before treatment, Cycle 1 Day 2, day 15 (pre-infusion and post-infusion), Cycle 2 (pre-infusion)</time_frame>
        <posting_date>01/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Severity of the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT)</title>
        <description>Proportion of patients rating their symptoms to be 7 or greater on a 0-10 scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool. Zero is &quot;not present&quot; and 10 is &quot;as bad as you can imagine. All patients with at least one valid questionnaire will be included in the anlyses. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity and symptom interference measures.</description>
        <time_frame>Baseline, week 4, week 8, and end of therapy</time_frame>
        <posting_date>01/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Core Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool</title>
        <description>Proportion of patients rating their symptoms to be 7 or greater on a 0-10 scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool. Zero is &quot;not present&quot; and 10 is &quot;as bad as you can imagine. All patients with at least one valid questionnaire will be included in the anlyses. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity and symptom interference measures.</description>
        <time_frame>Baseline, week 4, week 8, and end of therapy</time_frame>
        <posting_date>01/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Symptom Interference at the Time of Clinical Evaluation</title>
        <description>Proportion of patients rating their symptoms to be 7 or greater on a 0-10 scale using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool. Zero is &quot;not present&quot; and 10 is &quot;as bad as you can imagine. All patients with at least one valid questionnaire will be included in the anlyses. Differences of at least 2 points will be classified as the minimum clinically meaningful change in the symptom severity and symptom interference measures.</description>
        <time_frame>Baseline, week 4, week 8, and end of therapy</time_frame>
        <posting_date>01/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiological Response</title>
        <description>Magnetic resonance imaging (MRI) and contrast-enhanced (CE) MRI was used to evaluate tumor response. Response is defined by the Modified MacDonald criteria. Complete Response (CR) is complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. Partial Response, Non-Measurable (PRNM) is not applicable. Stable/No Response does not qualify for CR, PR or progression. Progression is 25% increase in the sum of products, of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any lesion/site, OR failure to return for evaluation due to health or deteriorating condition (unless clearly unrelated to this cancer).</description>
        <time_frame>End of therapy</time_frame>
        <posting_date>01/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Phase I adverse events collected within 4 week (28 day) cycle. Phase II evaluated for adverse events after each cycle for first 2 cycles and subsequently after each 2 cycles of treatment prior to initiating the next cycle.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Vorinostat + Bevacizumab</title>
          <description>Phase I Vorinostat starting dose 400 mg orally days 1 - 7 &amp; days 15 - 21 in combination with Bevacizumab fixed dose 10mg/kg IV on Days 1 &amp; 15 of 28 day cycle.</description>
        </group>
        <group group_id="E2">
          <title>Phase II: Bevacizumab</title>
          <description>Phase II Bevacizumab 10 mg/kg/dose IV on days 1 &amp; 15 of a 28 day cycle.</description>
        </group>
        <group group_id="E3">
          <title>Phase II: Bevacizumab + Vorinostat 400 mg</title>
          <description>Phase II Bevacizumab 10 mg/kg/dose IV Day 1 &amp; 15 + MTD of Vorinostat 400 mg/day by mouth on days 1 to 7 &amp; days 15 to 21 of a 28 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic nerve disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Ear and labyrinth disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>OCULAR SURFACE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL (Right homonymous hemianopsia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL (Right &amp; Left visual field deficits)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="20" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal (sensitivity to smell)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" events="23" subjects_affected="18" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Obstruction GI (STOMACH-small bowel nos)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="41"/>
                <counts group_id="E3" events="44" subjects_affected="32" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gait/walking (wide based ataxic hemiparetic)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gait/walking Impaired mobility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC (Neck NOS), cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC (Neck NOS), herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC (Neck NOS), (Urinary Tract NOS)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infection with Normal ANC (Wound), Herpes Z-back-perineal-scrutum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase (ALT) increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase (AST) increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hemoglobin Increase</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>International normalized ratio (INR) increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="17" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="15" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="17" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="32" subjects_affected="16" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="17" subjects_affected="8" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bicarbonate Serum-low</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="26" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" events="22" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypertriglycedidemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (Elevated BUN)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (elevated LDH)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (high chloride)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (low chloride)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (low creatinine)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (low protein)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (low uric acid)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness- Whole body/generalized</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>PAIN (BACK)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain (Neuropathic in perineal/buttock)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Facial muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E3" events="35" subjects_affected="23" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Movements involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="30" subjects_affected="17" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neuropathy, Numbness, Right sided</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neuropathy, Cranial (Pupil, Upper eyelid)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neuropathy, Sensory Legs/Toes tingling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pyramidal Tract Dysfunction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sensory loss left side</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mental Status Altered</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mood Alteration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Irregular Menses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>DECUBITUS Ulcer Sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bump at sutura site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Multiple scabs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation (hands &amp; knuckles)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="72" subjects_affected="26" subjects_at_risk="41"/>
                <counts group_id="E3" events="54" subjects_affected="21" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Gilbert</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-402-6383</phone>
      <email>gilbertmr@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

